Literature DB >> 29330927

Defined Serum-Free Medium for Bioreactor Culture of an Immortalized Human Erythroblast Cell Line.

Esmond Lee1,2, Zhong Ri Lim1, Hong-Yu Chen3, Bin Xia Yang3, Alan Tin-Lun Lam1, Allen Kuan-Liang Chen1, Jaichandran Sivalingam1, Shaul Reuveny1, Yuin-Han Loh3,4, Steve Kah-Weng Oh1.   

Abstract

Anticipated shortages in donated blood supply have prompted investigation of alternative approaches for in vitro production of red blood cells (RBCs), such as expansion of conditional immortalization erythroid progenitors. However, there is a bioprocessing challenge wherein factors promoting maximal cell expansion and growth-limiting inhibitory factors are yet to be investigated. The authors use an erythroblast cell line (ImEry) derived from immortalizing CD71+CD235a+ erythroblast from adult peripheral blood for optimization of expansion culture conditions. Design of experiments (DOE) is used in media formulation to explore relationships and interactive effects between factors which affect cell expansion. Our in-house optimized medium formulation produced significantly higher cell densities (3.62 ± 0.055) × 106  cells mL-1 , n = 3) compared to commercial formulations (2.07 ± 0.055) × 106  cells mL-1 , n = 3; at 209 h culture). Culture media costs per unit of blood is shown to have a 2.96-3.09 times cost reduction. As a proof of principle for scale up, ImEry are expanded in a half-liter stirred-bioreactor under controlled settings. Growth characteristics, metabolic, and molecular profile of the cells are evaluated. ImEry has identical O2 binding capacity to adult erythroblasts. Amino acid supplementation results in further yield improvements. The study serves as a first step for scaling up erythroblast expansion in controlled bioreactors.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cellular therapy; design of experiments; immortalized erythroblast; red blood cells bioreactor

Mesh:

Substances:

Year:  2018        PMID: 29330927     DOI: 10.1002/biot.201700567

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  3 in total

1.  The secrets of human stem cell-derived transfusable RBC for targeted large-scale production and clinical applications: A fresh look into what we need most and lessons to be learned.

Authors:  Jerard Seghatchian
Journal:  Transfus Apher Sci       Date:  2020-06-27       Impact factor: 1.764

Review 2.  Trends and targets of various types of stem cell derived transfusable RBC substitution therapy: Obstacles that need to be converted to opportunity.

Authors:  Francesco Lanza; Jerard Seghatchian
Journal:  Transfus Apher Sci       Date:  2020-09-06       Impact factor: 1.764

Review 3.  Clever Experimental Designs: Shortcuts for Better iPSC Differentiation.

Authors:  Ryota Yasui; Keisuke Sekine; Hideki Taniguchi
Journal:  Cells       Date:  2021-12-15       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.